GALECTIN THERAPEUTICS INC financial data

Symbol
GALT on Nasdaq
Location
Norcross, GA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 19% % -88%
Debt-to-equity -111% % 25%
Return On Equity 32% % -49%
Return On Assets -269% % -65%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64,472,792 shares 2.7%
Common Stock, Shares, Outstanding 64,472,792 shares 3.5%
Entity Public Float $112,000,000 USD 78%
Common Stock, Value, Issued $64,000 USD 3.2%
Weighted Average Number of Shares Outstanding, Basic 64,205,000 shares 3.1%
Weighted Average Number of Shares Outstanding, Diluted 64,205,000 shares 3.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $23,466,000 USD -30%
General and Administrative Expense $5,682,000 USD -3.3%
Operating Income (Loss) $29,148,000 USD 26%
Nonoperating Income (Expense) $8,155,000 USD -48%
Net Income (Loss) Attributable to Parent $37,303,000 USD 17%
Earnings Per Share, Basic 0 USD/shares 19%
Earnings Per Share, Diluted 0 USD/shares 19%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,525,000 USD -57%
Assets, Current $12,729,000 USD -56%
Property, Plant and Equipment, Net $0 USD
Operating Lease, Right-of-Use Asset $37,000 USD 42%
Other Assets, Noncurrent $136,000 USD -56%
Assets $12,865,000 USD -56%
Accounts Payable, Current $5,390,000 USD 93%
Employee-related Liabilities, Current $1,100,000 USD 3.9%
Accrued Liabilities, Current $5,038,000 USD -57%
Liabilities, Current $136,445,000 USD 440%
Operating Lease, Liability, Noncurrent $7,000 USD -87%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $136,445,000 USD 12%
Retained Earnings (Accumulated Deficit) $426,984,000 USD -9.6%
Stockholders' Equity Attributable to Parent $125,303,000 USD -33%
Liabilities and Equity $12,865,000 USD -56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,689,000 USD 36%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 64,472,792 shares 3.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11,525,000 USD -57%
Deferred Tax Assets, Valuation Allowance $90,343,000 USD 15%
Deferred Tax Assets, Gross $90,343,000 USD 15%
Operating Lease, Liability $37,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid $38,000 USD 15%
Property, Plant and Equipment, Gross $74,000 USD 0%
Operating Lease, Liability, Current $37,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year Two $19,000 USD 5.6%
Lessee, Operating Lease, Liability, to be Paid, Year One $22,000 USD 10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $63,057,000 USD 2.7%
Preferred Stock, Shares Issued 1,210,000 shares -2%
Preferred Stock, Shares Authorized 1,742,500 shares 0%
Additional Paid in Capital $301,127,000 USD 2.2%
Preferred Stock, Shares Outstanding 1,210,000 shares -2%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $2,056,000 USD -13%
Interest Expense $3,384,000 USD 167%